Allscripts Healthcare Solutions Inc (MDRX) Q2 2021 Earnings Call Transcript fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Life Sciences | News, Analysis, Insights - HIT Consultant
What You Should Know: - Qualio the trusted cloud quality management system software for the entire life sciences ecosystem announced their $50M Series B funding round led by Tiger Global. Menlo Ventures also joined this round, alongside the following current Qualio investors: Frontline Ventures, MHS Capital, Operator Partners, Sorenson Ventures, and Storm Ventures. - This latest round of funding will support Qualio’s efforts to expand accessibility of their electronic quality management
What You Should Know: - Thoma Bravo, a private equity investment firm focused on the software and technology-enabled services sector announced that it has reached an agreement to acquire Greenphire, a financial lifecycle management software for clinical trials, from The Riverside Company. Financial details were not disclosed for the pending transaction. - The acquisition, which is subject to customary regulatory approvals, is expecte
US Orthopedic Alliance Taps 2bPrecise to Power Precision Medicine Program
What You Should Know:
2bPrecise, a precision medicine company, announced that the US Orthopedic Alliance (USOA) is leveraging 2bPrecise’ pharmacogenomics (PGx) solution to help physicians identify potentially dangerous drug-gene interactions.
– The 2bPrecise platform will deliver workflow, data management and clinical decision functionality to USOA providers ordering pharmacogenomic tests (PGx). Specifically, doctors can leverage test results to make informed decisions about powerful pain medications, anticoagulants, antiemetics or other drugs they may prescribe for patients.
– By working with 2bPrecise, USOA will be bringing the benefits of PGx directly into its members’ provider workflows so they can make more informed decisions about powerful pain medications, anticoagulants or other drugs they may prescribe to patients.
Care Access Research has teamed up with
AstraZeneca to support the Phase III clinical trial for AZD7442, AstraZeneca’s long-acting monoclonal antibody combination for the potential prevention of COVID-19.
Using Care Access’s Mobile Sites On Demand, the two will develop, deploy and manage clinical research sites across the country to assess the safety and efficacy of AZD7442 for post-exposure prophylaxis and preemptive treatment.
“Traditional methods limit who can participate in a clinical trial and how quickly we can complete the clinical trial,” said Ahmad Namvargolian, CEO of Care Access, in a statement. “We are pleased to provide AstraZeneca the innovative capabilities they need to expedite clinical research operations for this important COVID-19 treatment candidate.”